Status of vaccine research and development for Campylobacter jejuni

Vaccine

Volumn 34, Issue 26, 2016, Pages 2903-2906

  Riddle, Mark S ^a   Guerry, Patricia ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

Campylobacter jejuni; Enteric vaccine development; Impact assessment; Travelers' diarrhea

Indexed keywords

ABC TRANSPORTER PEB1; BACTERIAL VACCINE; CAMPYLOBACTER JEJUNI VACCINE; CARRIER PROTEINS AND BINDING PROTEINS; LIPOOLIGOSACCHARIDE; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN; VACCINE;

ARTICLE; BACTERIAL STRAIN; CAMPYLOBACTER JEJUNI; CAMPYLOBACTERIOSIS; CONJUGATE; DEVELOPING COUNTRY; DRUG DESIGN; DRUG RESEARCH; FINANCIAL MANAGEMENT; IMMUNIZATION; INFECTION PREVENTION; PRIORITY JOURNAL; ANIMAL; ANTIGENIC VARIATION; CAMPYLOBACTER INFECTIONS; CLINICAL TRIAL (TOPIC); GASTROENTERITIS; HUMAN; IMMUNOLOGY; MEDICAL RESEARCH; MICROBIOLOGY; TRENDS;

ANIMALS; ANTIGENIC VARIATION; BACTERIAL VACCINES; BIOMEDICAL RESEARCH; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; CLINICAL TRIALS AS TOPIC; GASTROENTERITIS; HUMANS; RECOMBINANT PROTEINS; VACCINES, CONJUGATE;

EID: 84960509964     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.080     Document Type: Article

References (34)

1. Murray C.J., Vos T., Lozano R., Naghavi M., Flaxman A.D., Michaud C., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
2. Scallan E., Hoekstra R.M., Angulo F.J., Tauxe R.V., Widdowson M.A., Roy S.L., et al. Foodborne illness acquired in the United States-major pathogens. Emerg Infect Dis 2011, 17:7-15.
3. Park M.S., Kim Y.S., Lee S.H., Kim S.H., Park K.H., Bahk G.J. Estimating the burden of foodborne disease, South Korea, 2008-2012. Foodborne Pathog Dis 2015, 12:207-213.
4. Scharff R.L. Economic burden from health losses due to foodborne illness in the United States. J Food Prot 2012, 75:123-131.
5. Hoffmann S., Batz M.B., Morris J.G. Annual cost of illness and quality-adjusted life year losses in the United States due to 14 foodborne pathogens. J Food Prot 2012, 75:1292-1302.
6. Havelaar A.H., Haagsma J.A., Mangen M.J., Kemmeren J.M., Verhoef L.P., Vijgen S.M., et al. Disease burden of foodborne pathogens in the Netherlands, 2009. Int J Food Microbiol 2012, 156:231-238.
7. Kubota K., Kasuga F., Iwasaki E., Inagaki S., Sakurai Y., Komatsu M., et al. Estimating the burden of acute gastroenteritis and foodborne illness caused by Campylobacter, Salmonella, and Vibrio parahaemolyticus by using population-based telephone survey data, Miyagi Prefecture, Japan, 2005 to 2006. J Food Prot 2011, 74:1592-1598.
8. Tam C.C., O'Brien S.J., Adak G.K., Meakins S.M., Frost J.A. Campylobacter coli-an important foodborne pathogen. J Infect 2003, 47:28-32.
9. Thomas M.K., Murray R., Flockhart L., Pintar K., Pollari F., Fazil A., et al. Estimates of the burden of foodborne illness in Canada for 30 specified pathogens and unspecified agents, circa 2006. Foodborne Pathog Dis 2013, 10:639-648.
10. Coker A.O., Isokpehi R.D., Thomas B.N., Amisu K.O., Obi C.L. Human campylobacteriosis in developing countries. Emerg Infect Dis 2002, 8:237-244.
11. Kotloff K.L., Nataro J.P., Blackwelder W.C., Nasrin D., Farag T.H., Panchalingam S., et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013, 382:209-222.
12. Platts-Mills J.A., Kosek M. Update on the burden of Campylobacter in developing countries. Curr Opin Infect Dis 2014, 27:444-450.
13. Platts-Mills J.A., Babji S., Bodhidatta L., Gratz J., Haque R., Havt A., et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Global Health 2015, 3:e564-e575.
14. Kuwabara S., Yuki N. Axonal Guillain-Barre syndrome: concepts and controversies. Lancet Neurol. 2013, 12:1180-1188.
15. Riddle M.S., Gutierrez R.L., Verdu E.F., Porter C.K. The chronic gastrointestinal consequences associated with campylobacter. Curr Gastroenterol Rep 2012, 14:395-405.
16. Lee G., Pan W., Penataro Yori P., Paredes Olortegui M., Tilley D., Gregory M., et al. Symptomatic and asymptomatic Campylobacter infections associated with reduced growth in Peruvian children. PLoS Negl Trop Dis 2013, 7:e2036.
17. World Health Organization. The global view of campylobacteriosis: Report of an expert consultation, Available 〈www.who.int/iris/bitstream/10665/80751/1/9789241564601_eng.pdf.〉 2012.
18. The MAL-ED study: a multinational and multidisciplinary approach to understand the relationship between enteric pathogens, malnutrition, gut physiology, physical growth, cognitive development, and immune responses in infants and children up to 2 years of age in resource-poor environments. Clin Infect Dis 2014, 59(Suppl 4):S193-S206. Investigators M-EN.
19. Blaser M.J., Berkowitz I.D., LaForce F.M., Cravens J., Reller L.B., Wang W.L. Campylobacter enteritis: clinical and epidemiologic features. Ann Intern Med 1979, 91:179-185.
20. Blaser M.J., Taylor D.N., Echeverria P. Immune response to Campylobacter jejuni in a rural community in Thailand. J Infect Dis 1986, 153:249-254.
21. Black R.E., Levine M.M., Clements M.L., Hughes T.P., Blaser M.J. Experimental Campylobacter jejuni infection in humans. J Infect Dis 1988, 157:472-479.
22. Tribble D.R., Baqar S., Scott D.A., Oplinger M.L., Trespalacios F., Rollins D., et al. Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. Infect Immun 2010, 78:1750-1759.
23. Parkhill J., Wren B.W., Mungall K., Ketley J.M., Churcher C., Basham D., et al. The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable tracts. Nature 2000, 403:665-668.
24. Bacon D.J., Szymanski C.M., Burr D.H., Silver R.P., Alm R.A., Guerry P. A phase variable capsule is involved in virulence of Campylobacter jejuni 81-176. Mol Microbiol 2001, 40:769-777.
25. Maue A.C., Poly F., Guerry P. A capsule conjugate vaccine approach to prevent diarrheal disease caused by Campylobacter jejuni. Hum Vaccines Immunother 2014, 10:1499-1504.
26. Liu L., Lai W., Hu N., Zhang W., Chen T., Wang F., et al. [Evaluation of immunological efficiency induced by Campylobacter jejuni PEB1 DNA combined with PEB1 protein in mice]. Xi bao yu fen zi mian yi xue za zhi = Chin J Cell Mol Immunol 2014, 30:576-580.
27. Poly F., Serichatalergs O., Kuroiwa J., Pootong P., Mason C., Guerry P., et al. Completed Campylobacter jejuni capsule PCR multiplex typing system and its application to clinical strains from South East Asia. PLos One 2015, 10(12):e0144349.
28. Pike B.L., Guerry P., Poly F. Global distribution of Penner serotypes: a systematic review. PLoS One 2013, 8:e67375.
29. Monteiro M.A., Baqar S., Hall E.R., Chen Y.-H., Porter C.K., Bentzel D.E., et al. A capsule polysaccharide conjugate vaccine against diarrheal disease caused by Campylobacter jejuni. Infect Immun 2009, 77:1128-1136.
30. Tribble D.R., Baqar S., Carmolli M.P., Porter C., Pierce K.K., Sadigh K., et al. Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects. Clin Infect Dis 2009, 49:1512-1519.
31. Albert M.J., Haridas S., Ebenezer M., Raghupathy R., Khan I. Immunization with a double-mutant (R192G/L211A) of the heat-labile enterotoxin of Escherichia coli offers partial protection against Campylobacter jejuni in an adult mouse intestinal colonization model. PLoS One 2015, 10:e0142090.
32. Albert M.J., Haridas S., Adler B. Major outer membrane proteins from many Campylobacter species cross-react with cholera toxin. Clin Vaccine Immunol 2008, 15:859-862.
33. Islam A., Raghupathy R., Albert M.J. Recombinant PorA, the major outer membrane protein of Campylobacter jejuni, provides heterologous protection in an adult mouse intestinal colonization model. Clin Vaccine Immunol 2010, 17:1666-1671.
34. Albert M.J., Mustafa A.S., Islam A., Haridas S. Oral immunization with cholera toxin provides protection against Campylobacter jejuni in an adult mouse intestinal colonization model. mBio 2013, 4:e00246-e313.